Thank you, JT. Before I get started, as a reminder, during the fourth quarter of 2022, we began executing a plan to sell 1 of our subsidiaries, VA Lafayette, which owns a medical clinic whose sole tenant is the U.S. Veterans Administration. As part of our strategic shift away from the Leased Real Estate segment, VA Lafayette is included in discontinued operations and its assets and liabilities are reported as held for sale. The results of its operations are reported separately and not included in the results I'm about to discuss. Loss from continuing operations was $797,000 for the third quarter of 2023 compared to income from continuing operations of $38.9 million last year. The third quarter of 2022 includes a one-time net gain of $37.9 million on the sale of PWSC. Consolidated adjusted EBITDA was $2.3 million for the third quarter of 2023 compared to $3.6 million last year. Combined operating income for Extended Warranty and KSX was $2.8 million for the third quarter of 2023 compared to $3.2 million in the prior year. While the combined pro forma adjusted EBITDA, which excludes the results of PWSC that was sold last year, was $3.2 million in the third quarter of 2023 and $4.6 million in the third quarter of last year. Now, I'd like to break these down by reportable segment. In Extended Warranty, pro forma adjusted EBITDA was $2.1 million or 12.3% of pro forma revenue in the third quarter of 2023 compared to $3.8 million or 21.1% of pro forma segment revenue in the third quarter of last year. This decline was attributable to decreases in revenues, an increase in VSA claims, and a decrease in realized investment gains, which were partially offset by lower operating expenses. First, let me go through the revenue decline. Revenues were down at both our VSA companies and Trinity. VSA revenues were down only 1.1% from prior year due to the continuing impact of payment pressures on end consumers resulting from higher interest rate environment and continued higher-than-expected price of used automobiles. While the price of a used automobile has fallen since the beginning of this year, the declines for the end consumer are not occurring as quickly as anticipated. It is difficult to predict when these macroeconomic trends will begin to ease. However, a bright spot is IWS, which sells through credit unions where the decline in IWS contracts sold is much lower than the overall market decline in loans placed. At Trinity, as JT discussed, lower revenue was due to decreases in equipment breakdown and maintenance support services as a result of mild weather conditions, which results in fewer service calls and as well as long lead times on parts and installations. However, we continue to have strong backlog of orders in the Trinity Warranty business and as the supply chain frees up and machines are shipped and installed, we expect that the associated revenues will revert to historical growth trends. Next, the increase of VSA claims is due to an increase in the cost per claim or severity, while the number of claims or frequency was relatively stable. The increase in severity is a result of rising labor and parts costs, which continue to increase at rates higher than the general market inflation. Claims in the third quarter were $600,000 higher than the prior year, but were slightly down from Q2 2023 on both an absolute dollar basis and as a percentage of revenue. We continue to proactively assess our pricing to ensure that we are staying in front of any persistent claim severity increases. Operating expenses across all Extended Warranty companies were down about $600,000 excluding PWSC, which reflects initiatives put in place at Geminus and PWI since Brian Cosgrove took over both businesses about a year ago, as well as a continued scrutiny of all expense line items. Also contributing to Extended Warranty results is the investment income earned from our float and any gains or losses on other investments. As JT discussed, in the second quarter of -- sorry, the third quarter of 2022, IWS had very favorable realized gains from some of its investments, as well as a release of GAP product reserves, that's G-A-P product reserves. These totaled about $1.1 million and we didn't realize similar results in 2023. As we've discussed before, we invest our float, which was about $45 million at September 30, 2023, in U.S. bonds, municipal securities, and high-quality corporate bonds with an average duration of 2 to 3 years. As prior investments mature, we are able to reinvest at the current higher interest rates. This has resulted in TTM investment income as of 9/30/23 of $953,000 compared to just $369,000 for the year ago period. We believe the long-term outlook for Extended Warranty remains healthy and we continue to believe this is an attractive business to hold in our portfolio. At KSX, adjusted EBITDA was $1.1 million or 14.5% of segment revenue in the third quarter of 2023 compared to $778,000 or 20.4% of segment revenue in the third quarter of last year. And as a reminder, last year included just Ravix. At Ravix, profitability was up slightly compared to the prior year as the decline in revenue was essentially offset by a higher gross margin of 34.7% in the third quarter of 2023 versus 28% in the year ago quarter. The decline in revenue was due to a decrease in billable hours from lower-than-expected number of new clients that was partially offset by an increase in billing rates, the latter due to a shift in services mix, as well as price increases. CSuite delivered gross margin of 35.6%, which was in line with our expectations, but on lower-than-expected revenues. CSuite continues to rebuild its pipeline, which was disrupted during the acquisition process and has hired a business development team member to focus on its pipeline of opportunities. SNS delivered gross margin of 26.9%, which was higher than our expectations, but on lower-than-expected revenues. We continue to see a shift in mix from travel staffing to per diem staffing. Year-to-date, 58% of the shifts were per diem, which is the same year-to-date figure as the first 6 months of 2023. Also, the total number of shifts in Q3 2023 was down 20% to that in the year ago quarter. As a reminder, when we purchased SNS, our purchase price was based on go-forward results being lower than recent historical results at the time of acquisition, as we believe that staffing rates and the number of shifts were referred to levels more in line with those experienced pre-pandemic. At SNS, near-term growth is expected to come from expanding its base of travel nurses, as well as an expansion into new geographic areas. SNS has more seasonality than our other businesses, and the number of travel shifts is expected to improve as travel demand increases during the upcoming cold and flu season. Given we acquired SPI in early September, its contribution to the current quarter results was minimal. We plan to discuss SPI more on future calls. Turning now to our balance sheet. At the end of the third quarter of 2023, we had cash and cash equivalents of $20.2 million, compared to $64.2 million at the end of 2022. Cash used in operating activities from continuing operations was $9.6 million for the 9 months ended September 30, 2023, compared to cash provided by operations of $4.9 million in the first 9 months of last year. Our cash balance has been impacted by the following items this year: $5 million payment of TruPS deferred interest in Q1 of 2023; $2 million for the release of the Mendota escrow in Q1; $1.8 million of management fees paid in Q1 and Q2 of this year related to the final sale of commercial real estate investments; lower operating income from the Extended Warranty segment; $16.7 million of cash received from holders exercising warrants; and $3.3 million from the sale of Limbach stock. Our total outstanding debt is comprised of bank loans and 1 remaining trance of TruPS debt. Debt associated with the VA Lafayette is included in a separate line item on our balance sheet as liabilities held for sale. As a result, we had total outstanding debt of $40.9 million at the end of the third quarter of 2023, compared with $102.1 million at the end of last year. Net debt decreased to $20.8 million as of September 30, 2023, compared to $30.9 million at the end of last year -- I'm sorry, $37.9 million at the end of last year. Earlier this year, the Board approved a one-year securities repurchase program. Through October 31, 2023, we have repurchased 1,093,861 of our warrants and repurchased just over 250,000 shares of our common stock. After considering both stock and warrant repurchases, $4.1 million of stock repurchases or securities repurchases could be made through March 22 of next year. The repurchase of common stock is being held as treasury stock at cost and has been removed from our common shares outstanding. As you may recall, the company had a number of outstanding $5 strike warrants that expired on September 15, 2023. After accounting for warrants repurchased by the company, all but 39,000 warrants were exercised prior to expiration. In 2023, just over $3.3 million of our warrants were exercised, resulting in $16.7 million of cash to the company. You can see a breakdown by quarter in today's earnings release. During Q3, 2023, we completed the sale of all stock held in Limbach Holdings, Inc. and recorded a realized gain of $600,000. Total cash proceeds from the sales were $3.3 million. I would like to close by discussing our trailing 12-month adjusted EBITDA run rate. As JT indicated, our range is now $19 million to $20 million. We often get questions from investors about this metric, so I would like to explain a few things. This metric is not intended to be guidance by management regarding the future earnings of the company. Rather, it is intended to capture the 12-month earnings of what the company currently owns or has recently acquired. As such, it includes the following: the actual operating results of our Extended Warranty businesses for the prior 12 months, which includes the recent declines; the investment income associated with our Extended Warranty float adjusted to reflect higher earnings associated with the current interest rate environment; we do not factor in any expectations on realized gains or losses, much like we had at IWS in Q3 of last year. It also includes Ravix 12 months actual results, as well as CSuite actual 12 months results both pre- and post-acquisition. It includes 12 months of SNS results based on actual results since acquisition and adjusted results in order to reflect management's view that performance would revert to levels more in line with pre-pandemic results. And 12 months of results for SPI, DDI, and NICR based on adjusted results from our quality of earnings due diligence reports. In summary, while our Extended Warranty segment continued to experience some softness due to claims expense, it continued to perform and deliver the best quarterly results so far this year for the segment. We have added 2 companies to our KSX portfolios and hope to add a third early next year, which will enable us to deliver on our strategy of growth. Finally, we made further progress reducing our net debt, we were able to repurchase a meaningful amount of our securities, and we have a robust pipeline of acquisition opportunities in front of us. I'll now turn the call back over to the operator to open the line for questions. Paul?